Related Experiment Video
Updated: Jan 12, 2026

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
Published on: January 22, 2020
Targeting Interferon-Gamma (IFN-γ)-Related Signalling Pathways in Inflammatory Bowel Disease: Emerging Inhibitors and
Md Mizanur Rahaman1,2, Phurpa Wangchuk3,4, Subir Sarker1,2,5
1Biomedical Sciences and Molecular Biology, College of Medicine and Dentistry, James Cook University, Townsville, Queensland 4811, Australia.
Abstract:
Inflammatory bowel disease (IBD) encompasses a group of chronic and relapsing inflammatory disorders of the gastrointestinal tract, driven by a multifaceted interplay between genetic predisposition, environmental factors and dysregulated immune responses. Central to its immunopathogenesis is the aberrant activation of pro-inflammatory cytokine networks, among which interferon-gamma (IFN-γ) has been increasingly recognised as a critical mediator of mucosal damage and disease perpetuation. IFN-γ exerts pleiotropic effects on both innate and adaptive immune compartments, orchestrating a pathogenic immune milieu that disrupts intestinal epithelial integrity and sustains chronic inflammation. Recent therapeutic advances have focused on the modulation of IFN-γ signalling as a targeted approach to restoring intestinal homeostasis. A growing repertoire of IFN-γ inhibitors-including neutralising monoclonal antibodies (MAbs), small-molecule Janus kinase (JAK) inhibitors and bioactive phytochemicals-are being explored for their capacity to attenuate IFN-γ-driven inflammatory cascades. These agents offer distinct mechanistic profiles, targeting various nodes of the IFN-γ axis, and hold significant promise for addressing therapeutic gaps in refractory IBD. This review provides a comprehensive evaluation of emerging IFN-γ-targeted therapies, detailing their mechanisms of action, preclinical and clinical efficacy and translational potential. By elucidating the therapeutic landscape of IFN-γ modulation, this study aims to inform the development of more effective and personalised treatment strategies for patients with IBD.
More Related Videos
09:44Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
09:08Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Drugs for Treatment of Ulcerative Colitis in IBD